GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOS) » Definitions » Debt-to-Equity

BioPlus Acquisition (BioPlus Acquisition) Debt-to-Equity

: 0.04 (As of Jun. 2023)
View and export this data going back to 2022. Start your Free Trial

BioPlus Acquisition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.25 Mil. BioPlus Acquisition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $5.00 Mil. BioPlus Acquisition's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $121.85 Mil. BioPlus Acquisition's debt to equity for the quarter that ended in Jun. 2023 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BioPlus Acquisition's Debt-to-Equity or its related term are showing as below:

BIOS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02   Med: 0.02   Max: 7.22
Current: 0.04

During the past 2 years, the highest Debt-to-Equity Ratio of BioPlus Acquisition was 7.22. The lowest was 0.02. And the median was 0.02.

BIOS's Debt-to-Equity is not ranked
in the Diversified Financial Services industry.
Industry Median: 0.115 vs BIOS: 0.04

BioPlus Acquisition Debt-to-Equity Historical Data

The historical data trend for BioPlus Acquisition's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPlus Acquisition Annual Data
Trend Dec21 Dec22
Debt-to-Equity
0.02 0.02

BioPlus Acquisition Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.04
Competitive Comparison

For the Shell Companies subindustry, BioPlus Acquisition's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioPlus Acquisition Debt-to-Equity Distribution

For the Diversified Financial Services industry and Financial Services sector, BioPlus Acquisition's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BioPlus Acquisition's Debt-to-Equity falls into.


BioPlus Acquisition Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BioPlus Acquisition's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 5) / 222.998
=0.02

BioPlus Acquisition's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.25 + 5) / 121.851
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioPlus Acquisition  (NAS:BIOS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BioPlus Acquisition Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BioPlus Acquisition's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioPlus Acquisition (BioPlus Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOS) » Definitions » Debt-to-Equity
Comparable Companies
SBII GWII AHPA TACA CAS MCAA CORS AKIC CFFE TOAC GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
260 Madison Avenue, Suite 800, New York, NY, USA, 10026
Website
BioPlus Acquisition Corp is a blank check company.
Executives
Steven C. Fletcher 10 percent owner C/O LEE ENTERPRISES, INCORPORATED, 4600 EAST 53RD STREET, DAVENPORT IA 52807
Explorer Parent Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Founder Holdings Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Alex Serge Vieux 10 percent owner C/O COMPUTER ASSOCIATES INTER INC, ONE COMPUTER ASSOC PLAZA, ISLANDIA NY 11749
Bioplus Sponsor Llc 10 percent owner 544 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94010
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Louis G Lange director 3172 PORTER DRIVE, PALO ALTO CA 94034
Ross Haghighat director, officer: CEO and CFO C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Ronald W Eastman director 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Shawn Cross director 1825 K STREET SUITE 510, WASHINGTON DC 20006
Jonathan Rigby director, officer: Chief Business Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Glen Giovannetti director UNIT 6706, THE CENTER, 99 QUEEN'S ROAD CENTRAL, HONG KONG K3 00000